Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

AACR 2016

16 - 20 Apr 2016

Ernest N. Morial Convention Center, New Orleans, United States of America

The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year's theme, "Delivering Cures Through Cancer Science," reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients.

This cross-cutting, multidisciplinary program will include an outstanding roster of speakers, hundreds of invited talks, and more than 6,000 proffered papers from researchers around the globe. As always, the diversity of the AACR Annual Meeting program will give presenters a forum to share critical updates in all areas, as well as members of the audience an opportunity to actively participate in discussions with colleagues.

We are extremely grateful to the Program Committee Co-Chairpersons and Education Committee members for their dedication, enthusiasm, and guidance in shaping a program that will be both enjoyable and educational to attendees, and attract major media attention from around the world. Building upon the palpable energy at the close of last year's meeting, we will once again offer a Wrap-Up Plenary Session on Wednesday, April 20. Please plan to stay and join us to hear the most exciting and compelling basic, translational, clinical, and prevention-related highlights from the meeting. More information and program updates will be posted on a regular basis on the AACR website.

During the Annual Meeting, the AACR will celebrate a major milestone in publishing. The year 2016 marks the 100th anniversary of the AACR journals publication program, as well as the 75th anniversary of publishing the AACR journal, Cancer Research, which has a long tradition of being the most frequently cited journal in the field. The AACR published the first English-language cancer journal in 1916 and–100 years later–its publishing program has expanded to include eight high-impact, peer-reviewed scientific journals and an award-winning magazine for cancer survivors, patients, and their caregivers.

By attending this meeting, you will make fruitful connections, discuss new ideas, and hear from the world's thought leaders in cancer. We feel confident that you will leave the meeting with a sense of energy, inspiration, and focus for your work.

Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types

Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA

Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types ( Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA )

First outcome results from MINDACT breast cancer clinical trial

Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium

First outcome results from MINDACT breast cancer clinical trial ( Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium )

Genetics may influence risk for breast cancer after chest radiotherapy to treat childhood cancer

Dr Lindsay Morton - National Cancer Institute, Bethesda, USA

Genetics may influence risk for breast cancer after chest radiotherapy to treat childhood cancer ( Dr Lindsay Morton - National Cancer Institute, Bethesda, USA )

A presurgery combination therapy may improve outcomes for women with Her2-positive breast cancer

Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA

A presurgery combination therapy may improve outcomes for women with Her2-positive breast cancer ( Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA )

5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses

Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA

CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses ( Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA )

New investigational targeted therapeutic, entrectinib, shows early promise

Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA

New investigational targeted therapeutic, entrectinib, shows early promise ( Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA )

Paediatric and adult high grade gliomas: A tale of a histone tail

Dr Nada Jabado - McGill University, Montreal, Canada

Paediatric and adult high grade gliomas: A tale of a histone tail ( Dr Nada Jabado - McGill University, Montreal, Canada )

Galectins in tumour immunity

Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina

Galectins in tumour immunity ( Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina )

Treatment of relapsed myeloma with novel targeted and immune therapies

Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA

Treatment of relapsed myeloma with novel targeted and immune therapies ( Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA )

Targeting T regs in tumours

Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA

Targeting T regs in tumours ( Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA )

Multiplex IHC as biomarkers for cancer immunotherapy

Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA

Multiplex IHC as biomarkers for cancer immunotherapy ( Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA )

Integrating multiple omics information in the era of precision oncology

Dr Yu Shyr - Vanderbilt-Ingram Cancer Center, Nashville, USA

Integrating multiple omics information in the era of precision oncology ( Dr Yu Shyr - Vanderbilt-Ingram Cancer Center, Nashville, USA )

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity

Dr Thomas Dubensky - Aduro Biotech, Berkley, USA

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity ( Dr Thomas Dubensky - Aduro Biotech, Berkley, USA )

Successes and challenges in designing combination immunotherapy clinical trials for breast cancer

Prof Leisha Emmens - Johns Hopkins Kimmel Cancer, Baltimore, USA

Successes and challenges in designing combination immunotherapy clinical trials for breast cancer ( Prof Leisha Emmens - Johns Hopkins Kimmel Cancer, Baltimore, USA )

Breast cancer risk prediction models improved by adding multiple biological markers of risk

Dr Xuehong Zhang - Dana-Farber Cancer Institute, Boston, USA

Breast cancer risk prediction models improved by adding multiple biological markers of risk ( Dr Xuehong Zhang - Dana-Farber Cancer Institute, Boston, USA )

Physical activity may improve prostate cancer prognosis

Dr Ying Wang - American Cancer Society, Atlanta, USA

Physical activity may improve prostate cancer prognosis ( Dr Ying Wang - American Cancer Society, Atlanta, USA )

Inflammatory microenvironment regulates colorectal cancer progression

Dr Sergei Grivennikov - Fox Chase Cancer Center, Philadelphia, USA

Inflammatory microenvironment regulates colorectal cancer progression ( Dr Sergei Grivennikov - Fox Chase Cancer Center, Philadelphia, USA )

Mechanisms of immune escape in non-Hodgkin lymphoma

Dr Riccardo Dalla-Favera - Columbia University Medical Center, New York, USA

Mechanisms of immune escape in non-Hodgkin lymphoma ( Dr Riccardo Dalla-Favera - Columbia University Medical Center, New York, USA )

'Helper' T Cells effective in therapy, and shows early clinical responses in patients with metastatic cancer

Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA

'Helper' T Cells effective in therapy, and shows early clinical responses in patients with metastatic cancer ( Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA )

Innovations in assessing patient outcomes

Dr Heather Jim - Moffitt Cancer Center, Tampa, USA

Innovations in assessing patient outcomes ( Dr Heather Jim - Moffitt Cancer Center, Tampa, USA )

Repopulation of cancer stem cells in therapeutic resistance

Prof Keith Chan - Baylor College of Medicine, Houston, USA

Repopulation of cancer stem cells in therapeutic resistance ( Prof Keith Chan - Baylor College of Medicine, Houston, USA )

Technologies for personalised cancer immunotherapies

Prof James Heath - California Institute of Technology, Pasadena, USA

Technologies for personalised cancer immunotherapies ( Prof James Heath - California Institute of Technology, Pasadena, USA )

Modulating the DNA damage response: The role of cell cycle checkpoint inhibitors

Dr Shivaani Kummar - Stanford University, Stanford, USA

Modulating the DNA damage response: The role of cell cycle checkpoint inhibitors ( Dr Shivaani Kummar - Stanford University, Stanford, USA )

Multi-target S-DNA increases colorectal cancer screening among previously non-compliant patients

Dr Barry Berger - Exact Sciences, Madison, USA

Multi-target S-DNA increases colorectal cancer screening among previously non-compliant patients ( Dr Barry Berger - Exact Sciences, Madison, USA )

p62: Metabolism and the tumour microenvironment

Prof Jorge Moscat - Sanford Burnahm Prebys Medical Discovery Institute, La Jolla, USA

p62: Metabolism and the tumour microenvironment ( Prof Jorge Moscat - Sanford Burnahm Prebys Medical Discovery Institute, La Jolla, USA )

Cancer cells plasticity and drug resistance

Dr Rafaella Sordella - Cold Harbor Spring Laboratory, New York, USA

Cancer cells plasticity and drug resistance ( Dr Rafaella Sordella - Cold Harbor Spring Laboratory, New York, USA )

Targeted therapy shows continued promise in patients whose tumours had NTRK gene fusions

Dr David Hong - University of Texas MD Anderson Cancer Center, Houston, USA

Targeted therapy shows continued promise in patients whose tumours had NTRK gene fusions ( Dr David Hong - University of Texas MD Anderson Cancer Center, Houston, USA )

Drugging “undruggable” transcription factor drivers in cancer

Dr John Bushweller - Unviersity of Virgina, Virginia, USA

Drugging “undruggable” transcription factor drivers in cancer ( Dr John Bushweller - Unviersity of Virgina, Virginia, USA )

Pembrolizumab yielded durable responses in patients with advanced Merkel cell carcinoma

Dr Paul Nghiem - University of Washington, Seattle, USA

Pembrolizumab yielded durable responses in patients with advanced Merkel cell carcinoma ( Dr Paul Nghiem - University of Washington, Seattle, USA )

Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer

Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA

Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer ( Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA )

Elucidation and pharmacological targeting of tumour checkpoint dependencies

Dr Andrea Califano - Colombia University Medical Centre, New York, USA

Elucidation and pharmacological targeting of tumour checkpoint dependencies ( Dr Andrea Califano - Colombia University Medical Centre, New York, USA )

Identifying myeloid-driven biologies

Dr Brian Ruffell - Moffitt Cancer Center, Tampa, USA

Identifying myeloid-driven biologies ( Dr Brian Ruffell - Moffitt Cancer Center, Tampa, USA )

Metastasis intiation mediated by thrombospondin 2

Dr Ilaria Malanchi - Crick Institute, London, UK

Metastasis intiation mediated by thrombospondin 2 ( Dr Ilaria Malanchi - Crick Institute, London, UK )

New technology can potentially overcome CAR T-cell limitations

Dr Philip Low - Purdue University, West Lafayette, USA

New technology can potentially overcome CAR T-cell limitations ( Dr Philip Low - Purdue University, West Lafayette, USA )

Cell of origin role in cancer stem cell and GBM phenotype

Dr Luis Parada - Memorial Sloan Kettering Cancer Centre, New York, USA

Cell of origin role in cancer stem cell and GBM phenotype ( Dr Luis Parada - Memorial Sloan Kettering Cancer Centre, New York, USA )

New RAF-targeted therapeutic shows early promise against tumours with BRAF and RAS mutations

Dr Jayesh Desai - Royal Melbourne Hospital, Melbourne, Australia

New RAF-targeted therapeutic shows early promise against tumours with BRAF and RAS mutations ( Dr Jayesh Desai - Royal Melbourne Hospital, Melbourne, Australia )

MINDACT breast cancer clinical trial: First results and impact on future trial design

Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium

MINDACT breast cancer clinical trial: First results and impact on future trial design ( Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium )

Breast cancer research news from AACR President Nancy Davidson

Dr Nancy Davidson - AACR President, Philadelphia, USA

Breast cancer research news from AACR President Nancy Davidson ( Dr Nancy Davidson - AACR President, Philadelphia, USA )

Non-coding mutations driving chronic lymphocytic leukaemia

Dr Xose Puente - University of Oviedo, Oviedo, Spain

Non-coding mutations driving chronic lymphocytic leukaemia ( Dr Xose Puente - University of Oviedo, Oviedo, Spain )

SPF30 sunscreens delay melanoma incidence in preclinical model

Dr Christin Burd - Ohio State University, Columbus, USA

SPF30 sunscreens delay melanoma incidence in preclinical model ( Dr Christin Burd - Ohio State University, Columbus, USA )

Comparison of three different PD-L1 diagnostic tests shows a high degree of concordance

Dr Marianne Ratcliffe - AstraZeneca, UK

Comparison of three different PD-L1 diagnostic tests shows a high degree of concordance ( Dr Marianne Ratcliffe - AstraZeneca, UK )

Next-generation sequencing in the lymphoid malignancies

Dr Aaron Logan - UCSF, San Fransisco, USA

Next-generation sequencing in the lymphoid malignancies ( Dr Aaron Logan - UCSF, San Fransisco, USA )

Mutational clonality and intratumour heterogeneity as biomarkers for cancer immunotherapy

Dr Nicholas McGranahan - Crick Institute, London, UK

Mutational clonality and intratumour heterogeneity as biomarkers for cancer immunotherapy ( Dr Nicholas McGranahan - Crick Institute, London, UK )

Risk of breast cancer after chest radiotherapy may be affected by genetics

Dr Lindsay Morton - National Cancer Institute, Bethesda, USA

Risk of breast cancer after chest radiotherapy may be affected by genetics ( Dr Lindsay Morton - National Cancer Institute, Bethesda, USA )

Retroviral replicating vectors for cancer-targeted gene therapy and immunotherapy

Dr Noriyuki Kasahara - Miami University School of Medicine, Miami, USA

Retroviral replicating vectors for cancer-targeted gene therapy and immunotherapy ( Dr Noriyuki Kasahara - Miami University School of Medicine, Miami, USA )

NY-ESO-1 immunotherapy for ovarian cancer

Dr Kunle Odunsi - Roswell Park Cancer Institute, Buffalo, USA

NY-ESO-1 immunotherapy for ovarian cancer ( Dr Kunle Odunsi - Roswell Park Cancer Institute, Buffalo, USA )

Imaging tumour habitats - life at the edge

Robert Gillies - Moffitt Cancer Center, Tampa, USA

Imaging tumour habitats - life at the edge ( Robert Gillies - Moffitt Cancer Center, Tampa, USA )

Normal and neoplastic stem cells

Prof Irving L Weissman - Stanford University School of Medicine, Stanford, USA

Normal and neoplastic stem cells ( Prof Irving L Weissman - Stanford University School of Medicine, Stanford, USA )

More from ecancer